Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3539634

CC1CCN(c2cc(N3CCNCC3)ccc2C(N)=O)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.46
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ACVR1 Q04771 4/20 0.42
USP2 O75604 1/20 0.41
KDM4E B2RXH2 2/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
NR4A1 P22736 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CTPS1 P17812 1/20 0.39
TGFBR1 P36897 1/20 0.39
NTRK1 P04629 1/20 0.38
KIT P10721 1/20 0.38
AXL P30530 1/20 0.38
FLT3 P36888 1/20 0.38
JAK2 O60674 1/20 0.38
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3958572 0.92 CSF1R (0.52) CSF1RALDH1A1SMN1; SMN2ACVR1USP2
Trifluoroacetic Acid SCHEMBL3539638 0.87 CSF1R (0.50) CSF1RALDH1A1USP2KDM4EPOLB
Trifluoroacetic Acid SCHEMBL3543645 0.84 CSF1R (0.49) CSF1RALDH1A1SMN1; SMN2USP2KDM4E
Trifluoroacetic Acid SCHEMBL3539479 0.81 KDM4E (0.47) CSF1RALDH1A1KDM4EGAAHSD17B10
SCHEMBL3538621 0.79 CSF1R (0.51) CSF1RALDH1A1SMN1; SMN2USP2KDM4E
SCHEMBL3540352 0.78 ALDH1A1 (0.53) CSF1RALDH1A1SMN1; SMN2USP2POLB
Trifluoroacetic Acid SCHEMBL3070908 0.78 NPC1 (0.55) ALDH1A1SMN1; SMN2USP2KDM4EPOLB
SCHEMBL3539721 0.78 CSF1R (0.51) CSF1RALDH1A1SMN1; SMN2USP2KDM4E
SCHEMBL3539636 0.77 CSF1R (0.61) CSF1RALDH1A1SMN1; SMN2USP2GAA
SCHEMBL8255504 0.76 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2KDM4EPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES CSF1R 34/4885ALDH1A1 4796/4885SMN1; SMN2 1548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.